Industry
Biotechnology
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.
Loading...
Open
2.20
Mkt cap
84M
Volume
8.5K
High
2.33
P/E Ratio
-1.25
52-wk high
4.48
Low
2.20
Div yield
N/A
52-wk low
1.93
Portfolio Pulse from Benzinga Newsdesk
August 15, 2024 | 8:46 pm
Portfolio Pulse from Benzinga Newsdesk
August 15, 2024 | 10:18 am
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 8:46 pm
Portfolio Pulse from Benzinga Newsdesk
July 30, 2024 | 11:16 am
Portfolio Pulse from Benzinga Newsdesk
May 08, 2024 | 1:35 pm
Portfolio Pulse from Benzinga Newsdesk
May 07, 2024 | 8:41 pm
Portfolio Pulse from Benzinga Newsdesk
March 22, 2024 | 2:58 pm
Portfolio Pulse from Happy Mohamed
March 21, 2024 | 8:07 pm
Portfolio Pulse from Benzinga Newsdesk
March 04, 2024 | 9:03 pm
Portfolio Pulse from Benzinga Insights
January 10, 2024 | 5:31 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.